मुख्य बातें
- NIPT detects Down syndrome with 99% sensitivity and a false positive rate of just 0.04% — dramatically better than traditional first-trimester screening (85% sensitivity, 5% false positive rate)
- Detection rates differ by condition: trisomy 21 is 99%, trisomy 18 is 97-98%, trisomy 13 is 99%, and sex chromosome conditions are approximately 95%
- The false positive rate for the three main trisomies is 0.04-0.5%, meaning that the vast majority of "low-risk" results are truly reassuring
- Fetal fraction — the proportion of fetal DNA in the maternal blood — is the single most important factor affecting NIPT reliability; fractions below 4% may produce unreliable results
- All major NIPT platforms (Harmony, Panorama, MaterniT21, NIFTY) have comparable accuracy for core trisomies, but differ in methodology, turnaround time, and extended panel offerings
When your doctor recommends NIPT, or when you are considering it for early prenatal screening, the first question is inevitably: "How accurate is it?" The answer depends on what is being tested. For the core trisomies — Down syndrome, Edwards syndrome, and Patau syndrome — NIPT is remarkably accurate, with detection rates exceeding 97-99% and false positive rates well below 1%. For sex chromosome conditions and microdeletions, accuracy is good but lower. Understanding these numbers, what they mean in practical terms, and what factors can affect your specific result is essential for interpreting NIPT outcomes correctly.
This guide provides a detailed breakdown of NIPT accuracy by condition, explains the critical concept of fetal fraction, compares the major NIPT laboratory platforms available in Dubai, and clarifies what a "high-risk" or "low-risk" result actually means. If you have already had NIPT and want to understand your results, see our NIPT results explained guide. If you are trying to decide between NIPT and amniocentesis, see our NIPT vs amniocentesis comparison.
NIPT Detection Rates by Condition
NIPT accuracy is measured using two key metrics: sensitivity (the percentage of true positive cases that the test correctly identifies — also called the detection rate) and specificity (the percentage of true negative cases that the test correctly identifies as negative). A test with 99% sensitivity and 99.96% specificity means it catches 99 out of 100 affected pregnancies and correctly reassures 9,996 out of 10,000 unaffected pregnancies.
| Condition | Sensitivity (Detection Rate) | Specificity | False Positive Rate | PPV (Age 35) | PPV (Age 25) |
|---|---|---|---|---|---|
| Trisomy 21 (Down syndrome) | 99.0-99.7% | 99.96% | 0.04% | 91-99% | 50-80% |
| Trisomy 18 (Edwards syndrome) | 97.0-98.0% | 99.93% | 0.07% | 84-95% | 37-65% |
| Trisomy 13 (Patau syndrome) | 99.0% | 99.95% | 0.05% | 87-96% | 40-70% |
| Sex chromosome aneuploidies | 90-96% | 99.8% | 0.2% | Variable | Variable |
| Microdeletions (22q11.2, etc.) | 60-80% | 99.5-99.8% | 0.2-0.5% | Low | Low |
| Fetal sex determination | 99.9% | 99.9% | < 0.1% | N/A | N/A |
NIPT accuracy metrics by condition screened
An important nuance is the Positive Predictive Value (PPV) — the probability that a high-risk result actually represents a true positive. PPV depends not only on the test's sensitivity and specificity but also on the prevalence of the condition in the population being tested. Because trisomy 21 is more common in older mothers (approximately 1 in 100 at age 40), NIPT's PPV for Down syndrome in a 40-year-old is approximately 91-99% — meaning that a high-risk result is very likely to be correct. In a 25-year-old (where the prevalence is approximately 1 in 1,250), the PPV drops to 50-80% — meaning that about 20-50% of high-risk results in younger women may be false positives.
This is precisely why NIPT is classified as a screening test, not a diagnostic test. A high-risk NIPT result should always be followed by a diagnostic procedure (CVS or amniocentesis) before any irreversible decisions are made. Conversely, a low-risk NIPT result provides very strong reassurance — with a negative predictive value exceeding 99.9% for the core trisomies, regardless of maternal age.
Understanding False Positives and False Negatives
A false positive occurs when NIPT reports a high-risk result for a condition that the baby does not actually have. False positive rates for NIPT are very low — 0.04% for trisomy 21, 0.07% for trisomy 18, and 0.05% for trisomy 13. However, even these small percentages translate to real cases. If 10,000 women are screened, approximately 4 will receive a false positive result for Down syndrome. This is vastly better than traditional first-trimester combined screening, which has a false positive rate of approximately 5% (500 women out of 10,000 would receive a false positive).
The biological reasons for false positives include confined placental mosaicism (CPM) — the most common cause, where the placenta has a chromosomal abnormality that the baby does not share. Because NIPT analyses placental DNA (not fetal DNA directly), CPM can cause a high-risk result even when the baby is chromosomally normal. Other causes include maternal chromosomal mosaicism, a vanished twin with an abnormal karyotype, maternal cancer (which can shed abnormal DNA into the blood), and laboratory error.
A false negative occurs when NIPT reports a low-risk result for a condition that the baby actually has. False negative rates for the core trisomies are approximately 0.3-3%. The most common cause is low fetal fraction — if there is not enough fetal DNA in the sample, the chromosomal abnormality may not be detectable. True biological mosaicism (where some fetal cells are abnormal and others are normal) can also produce a false negative result if the abnormal cell line is underrepresented in the placenta.
For sex chromosome conditions and microdeletions, both false positive and false negative rates are higher than for the core trisomies. This is because sex chromosome conditions often involve mosaicism, and microdeletions involve very small chromosomal regions that are harder to detect using cell-free DNA analysis. If your NIPT includes these extended panels, it is especially important to confirm any high-risk results with diagnostic testing before acting on them.
Fetal Fraction: The Key Factor Affecting NIPT Reliability
Fetal fraction is the proportion of cell-free DNA in the maternal blood that comes from the placenta (representing the fetus). For NIPT to produce reliable results, a minimum fetal fraction of 4% is generally required, though most laboratories prefer 5% or higher. The average fetal fraction at 10-12 weeks is approximately 10-15%, increasing as pregnancy progresses.
If fetal fraction is below the laboratory's threshold, the result will be reported as "no call" or "test failure" — meaning the analysis could not produce a reliable result. This is not a positive or negative result; it simply means the test needs to be repeated. The no-call rate for NIPT is approximately 1-5% of all samples.
- Gestational age: Testing too early (before week 10) is the most common cause of low fetal fraction. Fetal fraction increases by approximately 0.1% per day during the first trimester, so even waiting one additional week can significantly improve the result
- Maternal BMI: Higher BMI is associated with lower fetal fraction because larger maternal blood volume dilutes the fetal DNA. Women with BMI > 30 have a 2-3 times higher rate of low fetal fraction and test failure compared to women with normal BMI
- Twin pregnancies: Each individual fetus contributes less DNA per fetus than a singleton, though the total fetal fraction may be similar. The per-fetus fetal fraction in twins is approximately 60-70% of what it would be in a singleton
- Certain chromosomal abnormalities: Pregnancies with trisomy 18 and trisomy 13 tend to have lower fetal fraction than unaffected pregnancies, which is one reason detection rates for these conditions are slightly lower than for trisomy 21
- Anticoagulant medications: Heparin therapy can interfere with some NIPT platforms, potentially affecting fetal fraction measurement
An important clinical note: a persistently low fetal fraction on repeat testing (two consecutive no-call results) may itself be associated with an increased risk of chromosomal abnormalities, particularly trisomy 18, trisomy 13, and triploidy. If your NIPT returns a no-call result twice, your doctor should discuss further evaluation options including diagnostic testing.
Get Reliable NIPT Results
DCDC Dubai Healthcare City offers NIPT with validated laboratory platforms and expert guidance on results interpretation. Book your test today.
NIPT Lab Comparison: Harmony, Panorama, MaterniT21, and NIFTY
Multiple NIPT platforms are available in Dubai, each using slightly different technology to analyse cell-free DNA. While all have comparable accuracy for the core trisomies, they differ in methodology, turnaround time, extended panel offerings, and specific features. Here is a detailed comparison:
| Feature | Harmony (Roche) | Panorama (Natera) | MaterniT21 (LabCorp) | NIFTY (BGI) |
|---|---|---|---|---|
| Technology | Targeted microarray | SNP-based | Whole genome sequencing | Whole genome sequencing |
| Trisomy 21 detection | > 99% | > 99% | > 99% | > 99% |
| Distinguishes maternal/fetal DNA | No | Yes (unique feature) | No | No |
| Egg donor pregnancies | Less reliable | Validated | Less reliable | Less reliable |
| Twins supported | Yes | Yes (including zygosity) | Yes | Yes |
| Microdeletion panel | Optional | Yes (22q11.2 standard) | Optional | Optional |
| Triploidy screening | No | Yes (unique feature) | No | No |
| Minimum fetal fraction | 4% | 2.8% (SNP advantage) | 4% | 3.5% |
| Turnaround time | 7-10 days | 7-14 days | 5-7 days | 7-10 days |
| Approximate cost (Dubai) | AED 1,200-2,000 | AED 1,500-2,500 | AED 1,200-2,000 | AED 999-1,500 |
Comparison of major NIPT platforms available in Dubai
Harmony uses targeted microarray technology that focuses specifically on chromosomes 21, 18, 13, X, and Y. This targeted approach means the test analyses fewer data points but with high precision for the target chromosomes. It is one of the most widely validated NIPT tests, with extensive published data from large clinical studies.
Panorama is unique in using single nucleotide polymorphism (SNP) analysis, which allows it to distinguish between maternal and fetal DNA at the individual level. This has two practical advantages: it can detect triploidy (a condition missed by other NIPT platforms), and it is validated for egg donor pregnancies (where other platforms may produce unreliable results because they assume the maternal and fetal DNA are from related individuals). Panorama also has a lower minimum fetal fraction requirement of 2.8%, which may reduce the no-call rate.
MaterniT21 was the first commercially available NIPT and uses whole genome sequencing — a massively parallel approach that sequences DNA fragments across the entire genome and counts the relative number of fragments from each chromosome. It has the fastest turnaround time of the major platforms and extensive clinical validation.
NIFTY (Non-Invasive Fetal TrisomY test by BGI Genomics) also uses whole genome sequencing and is widely available in the Middle East and Asia. It offers competitive pricing compared to the US-based platforms and has large validation studies from Chinese and international populations.
NIPT vs Traditional First-Trimester Screening: The Accuracy Gap
Before NIPT became available, first-trimester screening relied on the combined test: nuchal translucency (NT) ultrasound measurement plus maternal blood markers (PAPP-A and free beta-hCG) at 11-13 weeks. This combined test has a detection rate of approximately 85% for Down syndrome with a false positive rate of 5%. In practical terms, this means it misses about 15% of affected pregnancies and incorrectly flags 5% of unaffected pregnancies.
NIPT has fundamentally changed these numbers. With 99% sensitivity for trisomy 21 and a 0.04% false positive rate, NIPT catches nearly every affected pregnancy while producing 100 times fewer false positives than combined screening. This is a transformational improvement. However, it is important to note that NIPT and the NT scan are not redundant. The NT scan can detect structural abnormalities (such as certain heart defects) that NIPT cannot, and a significantly thickened NT has implications beyond chromosomal conditions. Many centres now recommend NIPT plus NT scan as the optimal first-trimester screening combination.
| Metric | Combined First-Trimester Screening | NIPT |
|---|---|---|
| Down syndrome detection rate | 85% | 99% |
| False positive rate | 5% | 0.04% |
| Unnecessary amniocenteses avoided | Baseline | 95%+ reduction |
| Timing | Week 11-13 | Week 10+ |
| Detects structural anomalies | Yes (via NT scan) | No |
| Cost | AED 500-1,200 | AED 999-2,500 |
NIPT vs traditional combined first-trimester screening accuracy comparison
How to Interpret Your NIPT Results Correctly
NIPT results are reported as "low risk" or "high risk" for each condition screened. Some laboratories provide a numerical risk (for example, "1 in 10,000 for trisomy 21") while others use a binary classification. Here is how to interpret each outcome:
- Low risk for all conditions: This is the result the vast majority of women (96-99%) receive. It provides strong reassurance — the negative predictive value exceeds 99.9% for the core trisomies. No additional diagnostic testing is needed based on NIPT alone
- High risk for trisomy 21: Given NIPT's high PPV for Down syndrome (especially in women 35+), this result has a high probability of being correct. Confirmatory diagnostic testing (CVS or amniocentesis) is recommended before any decisions
- High risk for trisomy 18 or 13: Confirmatory testing is essential, as the PPV for these rarer conditions is lower than for trisomy 21. Some high-risk results will be false positives due to confined placental mosaicism
- High risk for sex chromosome condition: PPV is lower than for trisomies — many high-risk results for sex chromosome conditions are false positives. Amniocentesis is recommended for confirmation, and genetic counselling is particularly important
- No call / test failure: The fetal fraction was too low for reliable analysis. Retesting in 1-2 weeks is recommended. Persistent no-call results after two attempts warrant discussion about diagnostic testing and additional monitoring
At DCDC Dubai Healthcare City, our NIPT service includes guidance on results interpretation. We ensure that every patient understands what their specific result means, what the next steps are (if any), and how the information fits into their overall prenatal care plan. For high-risk results, we coordinate referrals for genetic counselling and diagnostic testing.
Book Your NIPT at DCDC
Expert NIPT with validated laboratory platforms and comprehensive results counselling at DCDC Dubai Healthcare City.
Multiple NIPT panels available
DCDC में संबंधित सेवाएं
दुबई हेल्थकेयर सिटी में विशेषज्ञ देखभाल और उन्नत निदान
अक्सर पूछे जाने वाले प्रश्न
Understanding the Numbers Behind Your Results
NIPT is the most accurate non-invasive prenatal screening test ever developed. For the core trisomies — Down syndrome, Edwards syndrome, and Patau syndrome — it approaches the accuracy of diagnostic testing while carrying zero risk to the pregnancy. But accuracy is not a single number; it varies by condition, maternal age, fetal fraction, and the specific laboratory platform used. Understanding these nuances helps you interpret your results correctly and make informed decisions.
The most important takeaway is that NIPT is a screening test, not a diagnosis. A low-risk result provides extremely strong reassurance — you can be more than 99.9% confident that your baby does not have the screened conditions. A high-risk result is a strong indicator but not a certainty — confirmatory diagnostic testing is essential before any irreversible decisions. And a no-call result is not a positive or negative — it is an instruction to retest.
At DCDC Dubai Healthcare City, we offer NIPT with multiple validated platforms and provide comprehensive counselling on results interpretation. Whether your results are reassuringly low-risk or require further investigation, our team ensures you understand every aspect of your results and have a clear path forward.
स्रोत एवं संदर्भ
यह लेख हमारी चिकित्सा टीम द्वारा समीक्षित है और निम्नलिखित स्रोतों का संदर्भ देता है:
- ACOG Practice Bulletin — Screening for Fetal Chromosomal Abnormalities
- Gil et al. — Analysis of Cell-Free DNA in Maternal Blood: Meta-Analysis (Ultrasound in Obstetrics & Gynecology)
- SMFM — Cell-Free DNA Screening for Fetal Aneuploidy Statement
- International Society for Prenatal Diagnosis — NIPT Position Statement
- Norton et al. — Cell-Free DNA Analysis for Noninvasive Examination of Trisomy (NEJM)
इस साइट पर चिकित्सा सामग्री DHA-लाइसेंस प्राप्त चिकित्सकों द्वारा समीक्षित है। हमारी देखें संपादकीय नीति अधिक जानकारी के लिए।
लेखक
Dr. Hadi Komshi
Specialist Internal Medicine
MD, Internal Medicine Specialist
Dr. Hadi Komshi is a Specialist in Internal Medicine with expertise in preventive health and comprehensive patient care. He practices at DCDC Dubai Healthcare City.
Related Articles
NIPT Test Dubai: Everything You Need to Know
NIPT Test Results Explained
NIPT Gender Test Dubai: Early Baby Gender from Week 10
When Is the Best Time for NIPT?
blogPage.moreFromCategory
NIPT vs Amniocentesis vs NT Scan: Which Prenatal Test Do You Need?
और पढ़ेंNIPT Test Results Explained: High-Risk, Low-Risk & False Positives Guide
और पढ़ेंNIPT Test in Dubai: Cost, Accuracy, Timing & Complete Guide
और पढ़ेंCervical Cancer Screening in Dubai: Pap Smear, HPV Test & Guidelines
और पढ़ें
Best Menopause Doctor in Dubai: How to Find the Right Specialist
और पढ़ें